Adalimumab and Anti-Adalimumab Antibody, DoseASSURE™ ADL

CPT: 80145; 82397
Print Share


  • Anti-TNF-α Drug
  • DoseASSURE
  • Humira®

Test Includes

Adalimumab concentration; antiadalimumab antibody level; serial monitoring

Expected Turnaround Time

6 - 10 days

Specimen Requirements




2 mL

Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube


Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions

Refrigerate or freeze.

Stability Requirements



Room temperature

7 days


7 days


308 days

Freeze/thaw Cycle

Stable x6

Causes for Rejection

Plasma specimen received

Test Details


Monitor antiadalimumab therapy for individuals with Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions. This test provides adalimumab drug concentration levels as well as the level of antiadalimumab antibodies.


Electrochemiluminescence immunoassay (ECLIA)

Reference Interval

• Adalimumab drug level:

− Quantitation limit: <0.6 μg/mL

− Results ≥0.6 μg/mL indicate detection of adalimumab.

In the presence of antiadalimumab antibody, the adalimumab drug level reflects the antibody-unbound fraction of adalimumab concentration in serum.

• Antiadalimumab antibody:

− Quantitation limit: <25 ng/mL

− Results ≥25 ng/mL indicate detection of adalimumab antibody.

Additional Information

In the absence of antiadalimumab antibodies, the adalimumab drug level typically reflects the total adalimumab concentration in serum. In the presence of antiadalimumab antibodies, the adalimumab level typically reflects the antibody-unbound fraction of adalimumab concentration in serum.

This assay provides clinically valid antibody results at drug levels well above treatment targets (>30 μg/mL). Failure of adalimumab therapy may not always be due to the presence of antiadalimumab antibodies. In addition, the absence of antiadalimumab antibodies does not guarantee positive response to treatment.


Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007 Jul; 66(7):921-926. 17301106
Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009 Nov; 137(5):1628-1640. 19664627


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
503890 Adalimumab Drug + Antibody 99781-7 503866 Adalimumab Drug Level ug/mL 74117-3
503890 Adalimumab Drug + Antibody 99781-7 503867 Anti-Adalimumab Antibody ng/mL 74116-5
Reflex Table for Anti-Adalimumab Antibody
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 000000 Serial Monitoring 000000 Serial Monitoring N/A

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at